share_log

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

古根海姆以買入評級啓動對Myriad Genetics的報道,宣佈目標股價爲23美元
Benzinga ·  2023/12/14 06:36

Guggenheim analyst Subbu Nambi initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Buy rating and announces Price Target of $23.

古根海姆分析師Subbu Nambi以買入評級開始報道Myriad Genetics(納斯達克股票代碼:MYGN),並宣佈目標股價爲23美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論